DR ANTHONY MELVIN CRASTO,WorldDrugTracker, helping millions, A 90 % paralysed man in action for you, I am suffering from transverse mylitis and bound to a wheel chair,With death on the horizon, This will not stop me, Gods call only..........
DR ANTHONY MELVIN CRASTO Ph.D ( ICT, Mumbai) , INDIA 29Yrs Exp. in the feld of Organic Chemistry,Working for GLENMARK PHARMA at Navi Mumbai, INDIA. Serving chemists around the world. Helping them with websites on Chemistry.Million hits on google, world acclamation from industry, academia, drug authorities for websites, blogs and educational contributio
n

Friday 30 October 2015

Mohan Thiruvazhi



Mohan Thiruvazhi

Independent Business Development and Scientific Professional
Dr. Thiruvazhi has several years of scientific and management experience gained during his tenure at Therachem, HepatoChem,  Incedis Therapeutics, Abbott Labs, ChemBridge Research Labs (CRL), and GVK BIO. He has a proven track record of success in managing collaborations in medicinal chemistry, custom synthesis, and library synthesis. t Abbott Labs, his chemistry R&D efforts led to commercialization of assays for diagnosis of certain nutritional disorders, and diseases such as CAD, stroke, deep vein thrombosis, dementia, and Alzheimer. At CRL, he championed a chemistry research department dedicated to support clientsÂ' medicinal chemistry programs. He also managed and co-chaired a multi-year $100 million ChemBridge-Pfizer file enrichment collaboration. Starting from HTS results, Dr. Thiruvazhi has delivered high quality leads in internal and external medicinal chemistry collaborations. Prior to founding Incedis, he was an Associate Director at GVK Biosciences (an Indian Contract Research Organization) where his responsibilities spanned from collaboration management to business development. Dr. Thiruvazhi received his Ph.D. in synthetic chemistry from SUNY-Albany and was a Postdoctoral fellow at University of Pittsburgh and Research Triangle Institute

links

 

Experience






VP (Chemistry & Business Development)

Therachem Research Medilab Pvt Ltd
– Present (5 months)Greater Boston Area, MA
Therachem is an innovative, chemistry-driven global service provider for pharmaceutical and biopharmaceutical companies. Therachem believes in quality work and timely deliverance of services.

With high-end standard processes and guidance of technical experts, we provide comprehensive solutions to support medicinal chemistry research and chemical process research and development.

Therachem,a world-class research & development facility is located at Jaipur, Rajasthan, India.





VP Business Development

HepatoChem
– Present (6 months)Beverly, MA
Hepatochem is a C-H Activation chemistry technology company helping cleints with
(a) rapid analoging of hits/leads in a single chemical transformation in order to develop SAR or fix potential DMPK liabilities
(b) synthesize metabolites in single step in single digit mg to 100 mg quantities and deliver these in 2-4 weeks.
(c) supplying BMO (Biomimetic Oxidation Kits) for synthesis of metabolites and Glucuronidation kits that allows to identify reaction condition that produces glucuronide adduct of a drug compound. The reaction conditions are derivative of the Koenigs–Knorr reaction

visit our website at www.hepatochem.com

My responsibilities include but is not limited to

- acquisition of new clients, expansion of services to existing clients, helping clients best leverage Hepatochem technology.

- Strategy to expand technology to new service lines and secure funding for the same.








Independent Business Development and Chemistry Consultant

Independent Business Development and Chemistry Consultant
– Present (6 months)Greater Boston Area, MA
I help Life Science vendors and service providers

- develop and implement a well-defined sales strategy for increased revenue generation
- acquire new customer and expand services within existing customers
- out reach into North America or specific North American territory(ies)
- market on one or more products or services w/o committing to a full time business development professional
- define and implement marketing strategy
- retain and expand CRO-Client relationships via synthetic chemistry consulting





Head, Global Discovery Services (Sales & Marketing)

GVK Biosciences
(3 years 8 months)Greater Boston Area
I was responsible for a global team of business development professionals in US, Europe, APAC, and India. Delivered revenues in excess of budget and beat market growth by delivering 20% growth in drug discovery services. Built high performing teams in each territory and trained, motivated, and empowered them to deliver their targets.
Interacted very strongly with Operational Heads and next level leaders to ensure projects were delivered on time and under budget. Matrix interactions with Finance & Legal teams, and reporting responsibilities into the CEO and the executive leadership team.





President (Operations) and Co-founder

Incedis Therapeutics
(3 years)
Incedis is a San Diego drug discovery services company specializing in medicinal chemistry. We provide expertise in medicinal chemistry, synthetic chemistry, and project management to support our clients’ preclinical discovery chemistry efforts. We have seamlessly integrated U.S. based medicinal chemistry expertise with synthetic chemistry operations in India and manage these to U.S. standards. This integration has enabled us to provide unique, cost-effective, high-quality medicinal chemistry outsourcing solutions to our clients.

At Incedis, we

― strive to understand the needs, requirements, and objectives of our clients’ projects
― focus our efforts to help our clients achieve their project objectives
― take pride in providing value-added services to our clients





Associate Director (Business Development)

GVK Biosciences, Inc.
(9 months)
Responsible for US medicinal chemistry business development and management of collaborations





Associate Director

ChemBridge Research Laboratories
(6 years 1 month)
Championed new Chemistry Research Department, managed daily chemistry operations. Co-chaired Chemical Working Group of multi-year, multinational Global Pfizer/ChemBridge Collaboration in support of Pfizer's Discovery Efforts.

Executed external discovery collaborations and internal discovery efforts in kinase inhibitors.





Senior Scientist

Abbott Laboratories
(3 years 3 months)



Education





University of Pittsburgh

Post Doctoral Scientist, SYnthetic Organic Chemistry


Mohan Thiruvazhi, Ph.D. 1993, mthiruvazhi@gmail.com

Mohan Thiruvazhi











Since my graduation in 1993 from Professor Block’s group, I have traversed a diverse professional path starting with postdoc stints at the University of Pittsburgh and Research Triangle Institute (RTI), to chemistry in diagnostics, to heading a chemistry research department and managing global chemistry collaborations, to heading business development for a CRO in India.

 In Professor Block’s group, I was exposed to very exciting and rewarding chemistry research leading to more discoveries than I could handle. I thoroughly enjoyed sharing much of my Ph.D. days with all the other group members, and to date cherish those moments. The famous ‘What’s New?’ or its variant ‘Anything New?’ asked by Dr. Block daily or even multiple times in a day still rings in my ears.

Since January 2001, I have lived in beautiful San Diego with my wife Sujitha and kids Meghna (15 years) and Naveen (14 years)[as of January 2013]. Interestingly, my stay in San Diego has been the longest in a city thus far! As part of my business development responsibilities,
 Sujitha

Meghna

 Naveen


 I travel to the East Coast quite, often visiting Boston, NY and NJ cities, Philadelphia, and the Research Triangle Park area of NC.

I enjoy reading non-fiction books, am deeply interested in philosophy, love playing volleyball, and ardently follow cricket. I would love to be reconnected with Prof. Block’s past and present students. I can be reached at mthiruvazhi@gmail.com










Mohan Santhanam Thiruvazhi

Patent number: 8815906
Abstract: Provided are compounds of the formula (I): or a stereoisomer, tautomer, salt, hydrate or prodrug thereof that modulate tyrosine kinase activity, compositions comprising the compounds and methods of their use.
Type: Grant
Filed: March 18, 2009
Issued: August 26, 2014
Assignee: Chembridge Corporation
Inventors: Yahua Liu, Alexey Vyacheslavovich Anikin, Charles Chamchoumis Mikel, Douglas Eric McGrath, Goverdhan Reddy Vavilala, Jason Conrad Pickens, Aleksander Kadushkin, Luyong Jiang, Mohan Santhanam Thiruvazhi, Sergey Zozulya, Rajendran Vairagoundar, Tong Zhu, Alexander Chucholowski, Zheng Yan, Alisher Khasanov, Christina Gregor
Application number: 20130131062
Abstract: The present invention is directed to pyridazinone compounds of formula (I) and furan compounds of formula (II), pharmaceutical compositions of compounds of formula (I) and (II), kits containing these compounds, methods of syntheses, and a method of treatment of a proliferative disease in a subject by administration of a therapeutically effective amount of a compound of formulae (I) or (II). Both classes of compounds were identified through screening of a collection of small molecule libraries.
Type: Application
Filed: December 21, 2007
Issued: May 23, 2013
Inventors: Hakim Djaballah, Harold E. Varmus, David Shum, Romel Somwar, Alexander Chucholowski, Mohan Santhanam Thiruvazhi
Application number: 20130053376
Abstract: Provided are compounds of the formula (I): or a stereoisomer, tautomer, salt, hydrate or prodrug thereof that modulate tyrosine kinase activity, compositions comprising the compounds and methods of their use.
Type: Application
Filed: March 18, 2009
Issued: February 28, 2013
Inventors: Yahua Liu, Alexey Vyacheslavovich Anikin, Charles Chamchoumis Mikel, Douglas Eric McGrath, Goverdhan Reddy Vavilala, Jason Conrad Pickens, Aleksander Kadushkin, Luyong Jiang, Mohan Santhanam Thiruvazhi, Sergey Zozulya, Rajendran Vairagoundar, Tong Zhu, Alexander Chucholowski, Zheng Yan, Alisher Khasanov, Christina Gregor
Patent number: 8063225
Abstract: Provided are compounds of the formula (I): or a stereoisomer, tautomer, salt, hydrate or prodrug thereof that modulate tyrosine kinase activity, compositions comprising the compounds and methods of their use.
Type: Grant
Filed: August 10, 2007
Issued: November 22, 2011
Assignee: Chembridge Corporation
Inventors: Vlad E. Gregor, Yahua Liu, Alexey Anikin, Danny Peter Claude McGee, Charles Mikel, Douglas Eric McGrath, Goverdhan Reddy Vavilala, Jason C. Pickens, Alexander Kadushkin, Luyong Jiang, Mohan Santhanam Thiruvazhi, Sergey Zozulya, Rajendran Vairagoundar, Tong Zhu, Alexander Chucholowski, Thomas Webb, Vidyasagar Reddy Gantla, Zheng Yan
Application number: 20100210649
Abstract: The present invention is directed to pyridazinone compounds of formula (I) and furan compounds of formula (II), pharmaceutical compositions of compounds of formula (I) and (II), kits containing these compounds, methods of syntheses, and a method of treatment of a proliferative disease in a subject by administration of a therapeutically effective amount of a compound of formulae (I) or (II). Both classes of compounds were identified through screening of a collection of small molecule libraries.
Type: Application
Filed: December 21, 2007
Issued: August 19, 2010
Assignee: Sloan-Kettering Institute for Cancer Research
Inventors: Hakim Djaballah, Harold E. Varmus, David Shum, Romel Somwar, Alexander Chucholowski, Mohan Santhanam Thiruvazhi
Application number: 20080171769
Abstract: Provided are compounds of the formula (I): or a stereoisomer, tautomer, salt, hydrate or prodrug thereof that modulate tyrosine kinase activity, compositions comprising the compounds and methods of their use.
Type: Application
Filed: August 10, 2007
Issued: July 17, 2008
Inventors: Vlad E. Gregor, Yahua Liu, Alexey Anikin, Danny Peter Claude McGee, Charles Mikel, Douglas Eric McGrath, Goverdhan Reddy Vavilala, Jason C. Pickens, Alexander Kadushkin, Luyong Jiang, Mohan Santhanam Thiruvazhi, Sergey Zozulya, Rajendran Vairagoundar, Tong Zhu, Alexander Chucholowski, Thomas Webb, Vidyasagar Reddy Gantla, Zheng Yan


 

  • Spectroscopic, Theoretical, and Electrochemical Studies of 1,2-Dithiins, Richard S. Glass, John R. Pollard, T. Benjamin Schroeder, Dennis L. Lichtenberger, Eric Block, Russell Deorazio, Chuangxing Guo, Mohan Thiruvazhi. Phosphorus, Sulfur Silicon Relat. Elem., 1997, 120 (1), pp 439–440. DOI: 10.1080/10426509708545587
  • Significant Intramolecular Sulfur-Sulfur Interactions in cis- and trans-2,3-Dimethyl-5,6-dithiabicyclo[2.1.1]hexane, Eric Block, Richard. Glass, Russell DeOrazio, Dennis L. Lichtenberger, John R. Pollard, Erin E. Russell, T. Benjamin Schroeder, Mohan Thiruvazhi, Paul J. Toscano. Synlett, 1997, (SI), pp 525-528. DOI: 10.1055/s-1997-6136



 HIS SCHOOL..............

Don Bosco Matriculation School - Egmore,Chennai

www.dbegmore.com/
Don Bosco Matriculation School- Egmore,Chennai,School was founded in 1959 as ... of Madras,On 1st July 1978 it was upgraded as a Higher Secondary School.

13, Casa Major Road, Egmore, Chennai, Tamil Nadu 600008
044 2819 1274
 
 Map of Don Bosco Matriculation Higher Secondary School


 Image



.

 
 

 



////////////

John Y. L. Chung



John Y. L. Chung

Department of Process Chemistry, §Department of Chemical Process Development & Commercialization,Merck & Co., Inc., P.O. Box 2000, Rahway, New Jersey 07065, United States
MerckWhitehouse Station · Department of Process Chemistry
  • Department of Process Chemistry
    Whitehouse Station, United States
 
LINKS
https://www.researchgate.net/profile/John_Chung2
Department of Process Chemistry, §Department of Chemical Process Development & Commercialization,Merck & Co., Inc., P.O. Box 2000, Rahway, New Jersey 07065, United States
 
Application number: 20150197490
Abstract: The present invention relates to polymorphic forms of a compound of formula A: This compound is useful as a glucagon receptor antagonist and serves as a pharmaceutically active ingredient for the treatment of type 2 diabetes and related conditions, such as hyperglycemia, obesity, dyslipidemia, and the metabolic syndrome. Hydrates, hemihydrates, anhydrates and similar polymorphic forms are included.
Type: Application
Filed: March 26, 2015
Issued: July 16, 2015
Assignee: Merck Sharp & Dohme Corp.
Inventors: John Y. L. Chung, Yanfeng Zhang, Aaron S. Cote, Jeremy Scott, Yekaterina Vaynshteyn
Patent number: 9012488
Abstract: The present invention relates to polymorphic forms of a compound of formula A: This compound is useful as a glucagon receptor antagonist and serves as a pharmaceutically active ingredient for the treatment of type 2 diabetes and related conditions, such as hyperglycemia, obesity, dyslipidemia, and the metabolic syndrome. Hydrates, hemihydrates, anhydrates and similar polymorphic forms are included.
Type: Grant
Filed: February 21, 2014
Issued: April 21, 2015
Assignee: Merck Sharp & Dohme Corp.
Inventors: John Y. L. Chung, Yanfeng Zhang, Laura Artino, Aaron S. Cote, Donal Desmond, Jeremy Scott, Yekaterina Vaynshteyn
Application number: 20150087832
Abstract: The present invention is directed to processes for preparing beta 3 agonists of Formula (I) and Formula (II) and their intermediates. The beta 3 agonists are useful in the treatment of certain disorders, including overactive bladder, urinary incontinence, and urinary urgency.
Type: Application
Filed: October 22, 2012
Issued: March 26, 2015
Assignee: MERCK SHARP & DOHME, CORP.
Inventors: John Y.L. Chung, Kevin Campos, Edward Cleator, Robert F. Dunn, Andrew Gibson, R. Scott Hoerrner, Stephen Keen, Dave Liebermann, Zhuqing Liu, Joseph Lynch, Kevine M. Maloney, Feng Xu, Nobuyoshi Yasuda, Naoki Yoshikawa, Yong-Li Zhong
Application number: 20140242645
Abstract: The present invention is directed to a process for preparing a compound of formula I-11 through multiple-step reactions.
Type: Application
Filed: October 22, 2012
Issued: August 28, 2014
Inventors: John Y.L. Chung, Kevin Campos, Edward Cleator, Robert F. Dunn, Andrew Gibson, R Scott Hoerrner, Stephen Keen, Dave Lieberman, Zhuqing Liu, Joseph Lynch, Kevin M. Maloney, Feng Xu, Nobuyoshi Yasuda, Naoki Yoshikawa, Yong-Li Zhong
Application number: 20140171480
Abstract: The present invention relates to polymorphic forms of a compound of formula A: This compound is useful as a glucagon receptor antagonist and serves as a pharmaceutically active ingredient for the treatment of type 2 diabetes and related conditions, such as hyperglycemia, obesity, dyslipidemia, and the metabolic syndrome. Hydrates, hemihydrates, anhydrates and similar polymorphic forms are included.
Type: Application
Filed: February 21, 2014
Issued: June 19, 2014
Assignee: Merck Sharp & Dohme Corp.
Inventors: John Y. L. Chung, Yanfeng Zhang, Laura Artino, Aaron S. Cote, Donal Desmond, Jeremy Scott, Yekaterina Vaynshteyn
Patent number: 8697740
Abstract: The present invention relates to polymorphic forms of a compound of formula A: This compound is useful as a glucagon receptor antagonist and serves as a pharmaceutically active ingredient for the treatment of type 2 diabetes and related conditions, such as hyperglycemia, obesity, dyslipidemia, and the metabolic syndrome. Hydrates, hemihydrates, anhydrates and similar polymorphic forms are included.
Type: Grant
Filed: January 8, 2010
Issued: April 15, 2014
Assignee: Merck Sharp & Dohme Corp.
Inventors: John Y. L. Chung, Yanfeng Zhang, Laura Artino, Jennifer Baxter, Aaron S. Cote, Yekaterina Vaynshteyn, Donal Desmond, Jeremy Scott
Application number: 20120053350
Abstract: A process for the preparation of alkyl esters of N-protected oxo-azacycloalkylcarboxylic acids of Formula III: comprises contacting a ketosulfoxonium ylide of Formula II: with an iridium catalyst to obtain Compound III, wherein PG1 is an amine protective group; k is 0, 1, or 2; and RU, R1, R2, and R3 are defined herein. An embodiment of the process further com rises contacting a compound of Formula I: with a sulfoxonium halide of formula (RU)3S(O)Z, wherein Z is halide, in the presence of a strong base to obtain Compound II. Additional embodiments add a series of process steps leading to the synthesis of 7-oxo-1,6-diazabicyclo[3.2.1]octanes suitable for use as ?-lactamase inhibitors.
Type: Application
Filed: April 26, 2010
Issued: March 1, 2012
Inventors: Ian Mangion, Mark A. Huffman, Rebecca T. Ruck, Joseph Lynch, John Y.L. Chung, Benjamin Marcune
Application number: 20120010262
Abstract: The present invention relates to polymorphic forms of a compound of formula A: This compound is useful as a glucagon receptor antagonist and serves as a pharmaceutically active ingredient for the treatment of type 2 diabetes and related conditions, such as hyperglycemia, obesity, dyslipidemia, and the metabolic syndrome. Hydrates, hemihydrates, anhydrates and similar polymorphic forms are included.
Type: Application
Filed: January 8, 2010
Issued: January 12, 2012
Inventors: John Y.L. Chung, Yanfeng Zhang, Laura Artino, Jennifer Baxter, Aaron S. Cote, Donal Desmond, Jeremy Scott, Yekaterina Vaynshteyn
Patent number: 6620824
Abstract: The present invention relates to a process for preparing a compound of gonadotropin releasing hormone antagonists having a Formula I, in an efficient way, which involves preparation of key intermediates: 2-arylindole core; a chiral aziridine, in particular chiral nosyl aziridine; and an amine salt. The key process involves the coupling reaction of 2-arylindole and nosyl aziridine under boron trifluoride catalysis, which provides the final compound with unprecedented regioselectivity and enantioselectivity.
Type: Grant
Filed: April 5, 2002
Issued: September 16, 2003
Assignee: Merck & Co., Inc.
Inventors: John Y. L. Chung, Roger N. Farr, Guy R. Humphrey
Application number: 20030013876
Abstract: The present invention relates to a process for preparing a compound of gonadotropin releasing hormone antagonists having a Formula I, 1
Type: Application
Filed: April 5, 2002
Issued: January 16, 2003
Inventors: John Y. L. Chung, Roger N. Farr, Guy R. Humphrey
Patent number: 5846791
Abstract: Asymmetric bioreduction of a ketone substrate with yeast produces the corresponding (R)-alcohol of structure: ##STR1## a key intermediate in the synthesis of a .beta..sub.
Type: Grant
Filed: June 26, 1997
Issued: December 8, 1998
Assignee: Merck & Co., Inc.
Inventors: Michel M. Chartrain, John Y. L. Chung, Christopher Roberge
Patent number: 5792871
Abstract: Compound 9 is prepared by a 9-step ##STR1## process in an overall yield of about 35% from 3-acetylpyridine. Compound 10 is prepared by a seven-step ##STR2## process in an overall yield of about 30% from 3-acetyl pyridine. These compounds are key intermediates in the synthesis of Compound 11, an important .beta.-3 agonist useful in the treatment of obesity and diabetes.
Type: Grant
Filed: June 26, 1997
Issued: August 11, 1998
Assignee: Merck & Co., Inc.
Inventors: Michel M. Chartrain, Christopher Roberge, John Y. L. Chung, Dalian Zhao
Patent number: 5686607
Abstract: The invention is a highly efficient synthesis for making compounds of formula (iv) wherein R is C.sub.1-4 alkyl or benzyl; and R.sup.1, when present, is C.sub.1-4 alkyl, OH, O--C.sub.1-4 alkyl, or S--C.sub.1-4 alkyl; which are useful intermediates for making compounds such as those represented in formula (I).
Type: Grant
Filed: August 29, 1996
Issued: November 11, 1997
Assignee: Merck & Co., Inc.
Inventors: John Y. L. Chung, Dalian Zhao, David J. Mathre
Patent number: 5665882
Abstract: The invention is a highly efficient synthesis for making compounds of formula: ##STR1## wherein n=0, 1, R is C.sub.1-4 alkyl or benzyl; andR.sup.1, when present, is C.sub.1-4 alkyl, OH, O--C.sub.1-4 alkyl or S--C.sub.1-4 alkyl. The process involves silane-mediated conjugation of 4-vinylpyridine to a substituted lactam.
Type: Grant
Filed: August 29, 1996
Issued: September 9, 1997
Assignee: Merck & Co., Inc.
Inventors: John Y. L. Chung, Dalian Zhao, James M. McNamara, David L. Hughes
Patent number: 5340802
Abstract: Peptide analog type-B CCK receptor ligands or pharmaceutically-acceptable salts thereof, which are useful for treating central nervous system disorders, substance abuse, gastrointestinal disorders, endocrine disorders, eating-related disorders and for the treatment of shock, respiratory and cardiocirculatory insufficiencies.
Type: Grant
Filed: January 29, 1993
Issued: August 23, 1994
Assignee: Abbott Laboratories
Inventors: Kazumi Shiosaki, Alex M. Nadzan, David S. Garvey, Youe-Kong Shue, Mark S. Brodie, Mark W. Holladay, John Y.-L. Chung, Michael D. Tufano, Paul D. May
Patent number: 5314898
Abstract: Compounds having the formula I: ##STR1## are inhibitors of the 5-lipoxygenase enzyme and inhibitors of leukotriene biosynthesis. These compounds are useful as anti-asthmatic, anti-allergic, anti-inflammatory, and cytoprotective agents. They are also useful in treating angina, cerebral spasm, glomerular nephritis, hepatitis, endotoxemia, psoriasis, uveitis, and allograft rejection and in preventing the formation of atherosclerotic plaques.
Type: Grant
Filed: June 29, 1992
Issued: May 24, 1994
Assignees: Merck & Co., Inc., Merck Frosst Canada Inc.
Inventors: John Y. L. Chung, Robert A. Reamer, Yves Girard, Pierre Hamel
Patent number: 5312923
Abstract: The invention is a highly efficient synthesis for making compounds of the formula: ##STR1## wherein: R.sup.1 is a six membered saturated or unsaturated heterocyclic ring containing one or two heteroatoms wherein the heteroatoms are N; or NR.sup.6, wherein R.sup.6 is H or C.sub.1-10 alkyl;m is an integer from two to six; andR.sup.4 is aryl, C.sub.1-10 alkyl, or C.sub.4-10 aralkyl.
Type: Grant
Filed: February 16, 1993
Issued: May 17, 1994
Assignee: Merck & Co., Inc.
Inventors: John Y. L. Chung, David L. Hughes, Dalian Zhao
Patent number: 5221675
Abstract: Aza-spirocyclic compounds of formula (I) ##STR1## which enhance cortical cholinergic neurotransmission.
Type: Grant
Filed: February 26, 1991
Issued: June 22, 1993
Assignee: Abbott Laboratories
Inventors: John Y. L. Chung, David S. Garvey
Patent number: 5206373
Abstract: The invention is a highly efficient synthesis for making compounds of the formula: ##STR1## wherein: R.sup.1 is a six member saturated or unsaturated heterocyclic ring containing one or two heterocyclic atoms wherein the heteroatoms are N; or NR.sup.6, wherein R.sup.6 is H or C.sub.1-10 alkyl;m is an integer from two to six; andR.sup.4 is aryl, C.sub.1-10 alkyl, or C.sub.4-10 aralkyl.
Type: Grant
Filed: February 28, 1992
Issued: April 27, 1993
Assignee: Merck & Co., Inc.
Inventors: John Y. L. Chung, David L. Hughes, Dalian Zhao
//////John Y. L. Chung

Priyanka Bhatt

Priyanka Bhatt.

Priyanka Bhatt

Assistant Professor
LINKS

Dev Bhoomi Institute of Pharmacy & Research

www.devbhoomiinstitutes.in/...institutions/dev-bhoomi-Institute-of-phar...

DBGI Dehradun is the best college of Uttarakhand State. ..

Experience



Assistant professor

Dev Bhoomi Institute of Pharmacy and Research
July 2011 – Present (4 years 4 months)

Education



Dehradun Institute of Technology

M.pharma(pharmaceutics), Pharmacy
2009 – 2011


S.B.S.PGI

B. Pharmacy, Pharmaceutical Sciences
2005 – 2009

Honors & Awards

Got Young scientist Award in First National Conference on "Recent Advances in Pharmaceutical Biotechnology with emphasis on Biodiversity Conservation"-2012


Dev Bhoomi Institute of Pharmacy and Research
Map of Dev Bhoomi Institute of Pharmacy and Research
Dev Bhoomi Institute of Pharmacy and Research 
Address: Dev Bhoomi Campus, Chakrata Road, Bhauwala Rajawala Rd, Manduwala, Naugaon, Uttarakhand 248007
.

 page5
 page1

 page3




 



//////////Dev Bhoomi Institute of Pharmacy and Research, Naugaon, Uttarakhand, Priyanka Bhatt